CCCC — C4 THERAPEUTICS INC
Public company
InvestorLens aggregates public filing data to show which tracked investors reported holdings in this stock. Dollar values represent reported position values, not market capitalization, and may be delayed up to 45 days. Not a recommendation.
Sourced from SEC EDGAR public filings
About C4 THERAPEUTICS INC (CCCC)
C4 THERAPEUTICS INC (CCCC) appears in the most recent 13F filings of 3 tracked institutional investors. The largest disclosed position is held by Steve Cohen (Point72 Asset Management), valued at $18M. Across recent filings, tracked investors recorded 6 new positions, 0 increased, 0 reduced, and 0 exited. All data sourced from SEC 13F filings.
Based on recent institutional activity in CCCC
How many top investors track CCCC
A small number of top investors own this.
CCCC Ownership Composition
How C4 THERAPEUTICS INC is held across tracked investor types, based on reported 13F positions.
- Other95.9%
- Hedge Funds4.1%
Tracked investors reporting CCCC
- Steve CohenMar 31, 2026Point72 Asset ManagementShares169.1KValue$444.7K% Portfolio0.00%
- Ken GriffinMar 31, 2026Citadel AdvisorsShares2.6MValue$6.8M% Portfolio0.00%
- Izzy EnglanderMar 31, 2026Millennium ManagementShares1.4MValue$3.7M% Portfolio0.00%
Recent activity
- $2.3MFeb 17, 2026
- $3.7MMay 15, 2026
- New$18MFeb 17, 2026
- New$6.8MMay 15, 2026
- New$444.7KMay 15, 2026
- New$1.2MNov 14, 2025
Frequently asked questions
- How many institutional investors hold CCCC?
- 3 tracked institutional investors disclosed a position in CCCC (C4 THERAPEUTICS INC) in their most recent 13F filing.
- Who is the largest institutional holder of CCCC?
- Steve Cohen, Point72 Asset Management, holds the largest disclosed position in CCCC, valued at $18M.
- Did institutional ownership of CCCC increase or decrease?
- Across recent 13F filings, tracked investors recorded 6 new positions, 0 increased, 0 reduced, and 0 fully exited CCCC.
- Where does this CCCC ownership data come from?
- SEC Form 13F-HR filings, accessed via EDGAR. 13F filings are disclosed quarterly with a 45-day reporting delay and cover U.S.-listed long equity positions only. This is not investment advice.